SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-054487
Filing Date
2022-02-25
Accepted
2022-02-25 16:32:27
Documents
12
Period of Report
2022-02-24
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d317664d8k.htm   iXBRL 8-K 26377
  Complete submission text file 0001193125-22-054487.txt   152631

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA alna-20220224.xsd EX-101.SCH 2873
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE alna-20220224_lab.xml EX-101.LAB 18739
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE alna-20220224_pre.xml EX-101.PRE 11719
6 EXTRACTED XBRL INSTANCE DOCUMENT d317664d8k_htm.xml XML 3590
Mailing Address ONE NEWTON EXECUTIVE PARK SUITE 202 NEWTON MA 02462
Business Address ONE NEWTON EXECUTIVE PARK SUITE 202 NEWTON MA 02462 617-467-4577
Allena Pharmaceuticals, Inc. (Filer) CIK: 0001624658 (see all company filings)

IRS No.: 452729920 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38268 | Film No.: 22680682
SIC: 2836 Biological Products, (No Diagnostic Substances)